128 related articles for article (PubMed ID: 32240691)
1. Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal Impairment.
Higashimori M; Ishikawa K; Gillen M; Zhou D
J Pharm Sci; 2021 Jan; 110(1):438-445. PubMed ID: 32240691
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
[TBL] [Abstract][Full Text] [Related]
3. Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example with Lamivudine.
Shah K; Fischetti B; Cha A; Taft DR
Curr Drug Discov Technol; 2020; 17(3):387-396. PubMed ID: 30767745
[TBL] [Abstract][Full Text] [Related]
4. Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
You X; Wu W; Xu J; Jiao Z; Ke M; Huang P; Lin C
J Clin Pharmacol; 2020 Aug; 60(8):999-1010. PubMed ID: 32090332
[TBL] [Abstract][Full Text] [Related]
5. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
Mahmood I
Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
[TBL] [Abstract][Full Text] [Related]
6. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.
Wu W; Ke M; Ye L; Lin C
Eur J Clin Pharmacol; 2021 Jul; 77(7):989-998. PubMed ID: 33447912
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
Rhee SJ; Chung H; Yi S; Yu KS; Chung JY
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774
[TBL] [Abstract][Full Text] [Related]
8. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
[TBL] [Abstract][Full Text] [Related]
9. Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations.
Xu R; Tang H; Chen L; Ge W; Yang J
Br J Clin Pharmacol; 2021 Aug; 87(8):3244-3254. PubMed ID: 33528059
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations.
Guo L; Zhu X; Zhang L; Xu Y
Ther Adv Drug Saf; 2023; 14():20420986231220222. PubMed ID: 38157240
[TBL] [Abstract][Full Text] [Related]
11. Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations.
Wang R; Wang T; Han X; Chen M; Li S
Xenobiotica; 2024 Mar; 54(3):116-123. PubMed ID: 38344757
[TBL] [Abstract][Full Text] [Related]
12. Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
Zhou J; You X; Ke M; Ye L; Wu W; Huang P; Lin C
J Pharm Sci; 2021 Apr; 110(4):1853-1862. PubMed ID: 33556385
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.
Huang W; Czuba LC; Isoherranen N
J Pharmacol Exp Ther; 2020 Jun; 373(3):488-501. PubMed ID: 32198137
[TBL] [Abstract][Full Text] [Related]
14. In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform.
Spanakis M; Marias K
In Silico Pharmacol; 2014 Dec; 2(1):2. PubMed ID: 27502621
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.
De Sousa Mendes M; Hirt D; Urien S; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Benaboud S
Br J Clin Pharmacol; 2015 Nov; 80(5):1031-41. PubMed ID: 26011128
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling and Dose Adjustment of Teicoplanin in Pediatric Patients With Renal Impairment.
Xu J; Lin R; Chen Y; You X; Huang P; Lin C
J Clin Pharmacol; 2022 May; 62(5):620-630. PubMed ID: 34761398
[TBL] [Abstract][Full Text] [Related]
18. A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment.
Ye L; Ke M; You X; Huang P; Lin C
J Pharm Sci; 2020 Sep; 109(9):2909-2918. PubMed ID: 32565352
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients.
Cui C; Li X; Liang H; Hou Z; Tu S; Dong Z; Yao X; Zhang M; Zhang X; Li H; Zuo X; Liu D
Biopharm Drug Dispos; 2021 Jan; 42(1):24-34. PubMed ID: 33340419
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population.
Yee KL; Li M; Cabalu T; Sahasrabudhe V; Lin J; Zhao P; Jadhav P
J Clin Pharmacol; 2018 Mar; 58(3):364-376. PubMed ID: 29077203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
